Advanced searches left 3/3

Alzheimer's Disease - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 14 November 2022

* If you want to update the article please login/register

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol

ADNI3's primary aim is to determine the correlations among the clinical, cognitive, imaging, genetic, and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease, as the disease progresses from normal age to dementia, from mild cognitive impairment to mild cognitive impairment. ADNI3's research into AD biomarkers is ongoing in academia and industry, and it continues to be a public/private partnership between academia and industry to examine AD biomarkers. ADNI will continue to research ADNI's neuroscience, identify diagnostic and prognostic indicators, identify outcome measures that can be used in clinical trials, and help develop the most effective clinical trial scenarios. Across three cohorts: cognitively normal*, mild cognitive impairment, and mild Alzheimer's Disease dementia are all expected to be enrolled. At 59 locations in the United States and Canada, participants aged 55 to 90 will be enrolled from 59 sites. Only for the cognitively healthy cohort is currently recruiting non-Caucasian students.

Source link: https://clinicaltrials.gov/ct2/show/NCT02854033


Anti-viral Therapy in Alzheimer's Disease

HSV1 can also penetrate the brain by olfactory neurons directly. HSV1 reactivation is linked to tau hyperphosphorylation in mice and may also be involved in tau propagation across neurons. Cognitive impairment in HSV seropositive patients in various patient groups and healthy adults has been documented, as well as in healthy adults, and antiviral therapies have demonstrated potent resistance against peripheral HSV infection. The research team will carry out the first-ever clinical trial to specifically address AD's long-standing viral etiology hypothesis, which claims that viruses, particularly the very common HSV1 and HSV2, may be etiologic or contribute to AD's pathology. Patients treated with valacyclovir are expected to have less amyloid loss and performance than placebo, and, when using 18F-Florbetapir PET imaging, the 78-week trial showed less amyloid accumulation than placebo. Patients treated with valacyclovir were expected to have less binding increases in 18F-MK-6240 binding than those treated with placebo from baseline to 78 weeks, thanks to the use of tau PET imaging with the tracer 18F-MK-6240 at baseline and 78 weeks. With changes to outcome measures, investigators will collect CSF A93b2 (tau) in patients with lumbar puncture, plasma, and CSF acyclovir, assayed to discover the degree of CNS penetration of valacyclovir in mild AD.

Source link: https://clinicaltrials.gov/ct2/show/NCT03282916


Shanghai At Risk for Alzheimer's Disease: a Cohort Study

This is a prospective cohort study focusing on the first-degree relatives of Alzheimer's disease patients. This research is of utmost importance in establishing novel guidelines for the prevention and management of dementia in China's Chinese population, as well as clinicians' ability to detect AD in first-degree relatives.

Source link: https://clinicaltrials.gov/ct2/show/NCT05597410


PET Measures of CSF Clearance in Preclinical Alzheimer's Disease

a future amyloid lesions PiB-PET or Florbetaben-PET; b brain atrophy MRI; and cognitive decline are among the potential causes of: a future amyloid lesions, which is predicted over five years, a two-year longitudinal research designed to measure CSF clearance measured with the tau tracer [18F]-MK6240. The investigators claim to conclude over five years, with the exception that reduced CSF clearance measured with the tau tracer.

Source link: https://clinicaltrials.gov/ct2/show/NCT03663387


University of Washington Alzheimer's Disease Research Center (UW ADRC) Imaging & Biomarker Core

The particular pattern of tau deposition with tau PET will be investigated by a sub-cohort of UW ADRC Clinical Core participants with amyloid deposition and modest degrees of cognitive impairment. With tau PET, the specific pattern of tau deposition with tau PET will be investigated as well as normal cognition, or A+ by CSF or amyloid PET and normal cognition. Dr. Grabowski, the PI, will perform and analyze these scans, as well as store the results in the University of Washington Medical Center's Integrated Brain Imaging Center, which is managed by the Integrated Brain Imaging Center. We promote research synergism and productivity in UW studies of Alzheimer's disease and related dementias by standardizing and enhancing the collection of imaging and CSF for research participants with Alzheimer's disease and related dementias under the ADRC.

Source link: https://clinicaltrials.gov/ct2/show/NCT04437290


TANYCYTES' ROLE IN ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA: ARE THEY THE KEY TO WELL AGING?

However, diffusion is controlled by specialized ependymoglial cells, the tanycytes, which act as a barrier between the ME and the third ventricle and control blood-borne molecules into the hypothalamus, despite the lack of blood-brain barrier at brain microvessels. Previous research from our lab and the ERC consortium has highlighted the importance of tanycytes not only in the incorporation of neurohormones from neuroendocrine nerve terminals into pituitary portal blood circulation, but also in the transport of circulating leptin into the hypothalamus. Hence, hypothalamic dysfunction in AD and FTD can arise either from neuroendocrine dysregulation, direct neuronal loss, or from defective transport to hormones like leptin. This research seeks to establish that leptin transport through tanycytes is early changed in FTD and AD, as well as correlates.

Source link: https://clinicaltrials.gov/ct2/show/NCT05288842


Perturbation Training for Reducing Falls in People With Alzheimer's Disease

People with mild Alzheimer's disease can learn fall prevention skills from the exposure to large-scale perturbations, according to our aim. In Aim 1: people with Alzheimer's disease will be able to adapt to large-scale external disturbances and develop fall resistance motor skills; and 3 to see if people with Alzheimer's disease can generalize fall resistant skills to various contexts; and 4 to determine whether people with Alzheimer's disease can test fall resistant motor skills will be compared between groups; and 3 to determine whether people with Alzheimer's disease can generalize fall resistant skills to different environments.

Source link: https://clinicaltrials.gov/ct2/show/NCT05205980


Hyperspectral Retinal Observations for the Cross-sectional Detection of Alzheimer's Disease

Overwhelming evidence reveals how lifestyle habits can often greatly reduce the chance of getting the disease or delay its onset. Different researchers have published papers on the possibility of assigning a score to Alzheimer's status based on hyperspectral scans of the retina. These findings were based on images taken with hyperspectral cameras with a different working principle than the Mantis Photonics camera. With a machine that is more modular and lower in cost, the Mantis Photonics camera's working principle allows for the production of a hyperspectral retinoscopy with the same spectral range and a similar or higher spectral resolution. There is also reason to hypothesize retinal scans obtained with the Mantis Photonics camera and can be used for the same classification task. For testing patients with Normal Pressure Hydrocephalus, the automated tablet computer cognitive assessment test CoGNIT has established validity, replicability, and sensitivity. The recent feasibility of doing research in Mild Cognitive Impairment was confirmed. After shunt surgery and cognitive enhancement after shunt surgery, CoGNIT was more sensitive to cognitive decline at baseline and cognitive enhancement after shunt surgery than the Mini-Mental State Examination. One can therefore doubt the likelihood of normal repeatability of the blood test findings, which can be questioned. The objective of this research is to determine, develop, and compare non-invasive methods for the assessment of patients with mild cognitive impairment, particularly the Mantis Photonics hyperspectral camera with classification machine learning software in combination with Dr. Behrens' Computationit test.

Source link: https://clinicaltrials.gov/ct2/show/NCT05604183

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions